XOMA Financials: Xoma Royalty Corp AI Analysis

Home

Stock

XOMA

Financials

XOMA Financial

Xoma Royalty Corp

-100%

$-29.77

As of today:Mar 24, 17:06:16 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$29.77

Open

Day's Range

52 week range

Volume

Avg.Volume

410.0K

Dividend yield

1.80%

EPS (TTM)

1.91

Market Cap

What is XOMA?

XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

XOMA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	47	28	4	6	38	29
Revenue Growth (YoY)	104%	600%	-33%	-84%	31%	61%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	32	27	25	23	20	16
Research & Development	2	2	0	0	0	0
Operating Expenses	37	30	30	23	20	16
Other Non Operating Income (Expenses)	2	0	--	0	0	0
Pretax Income	16	-19	-40	-17	15	11
Income Tax Expense	-5	-5	0	0	0	-1
Net Income	9	-19	-46	-22	7	9
Net Income Growth	-121%	-59%	109%	-413.99%	-22%	-1,000%
Shares Outstanding (Diluted)	18.14	11.7	11.47	11.41	12.19	11.5
Shares Change (YoY)	55%	2%	1%	-6%	6%	31%
EPS (Diluted)	0.54	-1.64	-4.03	-1.98	0.65	0.78
EPS Growth	-114.99%	-59%	104%	-405%	-17%	-438.99%
Free Cash Flow	-14	-33	-18	-28	22	10
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	19.14%	-3.57%	-650%	-283.33%	44.73%	41.37%
Profit Margin	19.14%	-67.85%	-1,150%	-366.66%	18.42%	31.03%
Free Cash Flow Margin	-29.78%	-117.85%	-450%	-466.66%	57.89%	34.48%
EBITDA	11	-1	-26	-17	17	12
EBITDA Margin	23.4%	-3.57%	-650%	-283.33%	44.73%	41.37%
D&A For EBITDA	2	0	0	0	0	0
EBIT	9	-1	-26	-17	17	12
EBIT Margin	19.14%	-3.57%	-650%	-283.33%	44.73%	41.37%
Effective Tax Rate	-31.25%	26.31%	0%	0%	0%	-9.09%

Follow-Up Questions

What are Xoma Royalty Corp's key financial statements?



According to the latest financial statement (Form-10K), Xoma Royalty Corp has a total asset of $221, Net loss of $-19

What are the key financial ratios for XOMA?



Xoma Royalty Corp's Current ratio is 1.58, has a Net margin is -67.85, sales per share of $2.39.

How is Xoma Royalty Corp's revenue broken down by segment or geography?



Xoma Royalty Corp largest revenue segment is Pharmaceutical, at a revenue of 4,758,000 in the most earnings release.For geography, United States is the primary market for Xoma Royalty Corp, at a revenue of 3,658,000.

Is Xoma Royalty Corp profitable?



no, according to the latest financial statements, Xoma Royalty Corp has a net loss of $-19

Does Xoma Royalty Corp have any liabilities?



yes, Xoma Royalty Corp has liability of 139

How many outstanding shares for Xoma Royalty Corp?



Xoma Royalty Corp has a total outstanding shares of 11.95

Xoma Royalty Corp (XOMA) Financial

XOMA Stock Price Chart